Generation of lymphocytes potentiated against leukemic lymphoblasts by stimulation using leukemic cell lysate-pulsed dendritic cells in patients with acute lymphoblastic leukemia and measurement of in vitro anti-leukemic cytotoxicity

Hematology

Volumn 17, Issue 1, 2012, Pages 15-22

  Lim, Ji Hun ^a   Park, Chan Jeoung ^a   Kim, Mi Jung ^a   Jang, Sungsoo ^a   Chi, Hyun Sook ^a   Lee, Jung Hee ^a   Lee, Je Hwan ^a   Lee, Kyoo Hyong ^a   Im, Ho Joon ^a   Seo, Jong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute lymphoblastic leukemia; In vitro anti leukemic cytotoxicity; Leukemic cell lysate pulsed dendritic cells

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL LYSATE; CHILD; CLINICAL ARTICLE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA REMISSION; LYMPHOBLAST; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; T LYMPHOCYTE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84863098443     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13221316477453     Document Type: Article

References (25)

1. Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS, et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol. 2001;167(10):6021-6030.
2. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13-27.
3. Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001;98(13):3750-3756.
4. Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61(18): 6846-6850.
5. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96(4):1480-1489.
6. Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res. 1999;18(4):485-492.
7. Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006;34(10):1403-1412.
8. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 2002;62(10):2861-2868.
9. Delluc S, Tourneur L, Fradelizi D, Rubio MT, Marchiol-Fournigault C, Chiocchia, et al. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method. Cancer Immunol Immunother. 2007;56(1):1-12.
10. Decker WK, Xing D, Li S, Robinson SN, Yang H, Yao X, et al. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine. 2006;24(16):3203-3216.
11. Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, et al. The quality and quantity of leukemiaderived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother. 2010;33(5):523-537.
12. Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells. 2000;18(2):139-147.
13. Mohty M, Isnardon D, Blaise D, Mozziconacci MJ, Lafage-Pochitaloff M, Briere F, Gastaut JA, et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia. 2002; 16(11):2267-2274.
14. Tsuchiya T, Hagihara M, Shimakura Y, Ueda Y, Gansuvd B, Munkhbat B, et al. The generation of immunocompetent dendritic cells from CD34z acute myeloid or lymphoid leukemia cells. Int J Hematol. 2002;75(1):55-62.
15. Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by 'leukemic dendritic cells' derived from blast cells in acute myeloid leukemia. Blood. 2001;97(9):2764-2771.
16. Draube A, Beyer M, Wolf J. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte- derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur J Haematol. 2008;81(4):281-288.
17. Decker T, Lohmann-Metthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115:61-69.
18. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature. 1992;360(6401):258-261.
19. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89(4):1133-1142.
20. Coleman S, Throp D, Fisher J, Bailey-Wood R, Lim SH. Cytokine enhancement of immunogenicity in chronic myeloid leukaemia. Leukemia. 1997;11(12):2055-2059.
21. Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher. 2004;19(2):66-70.
22. Lee JJ, Nam CE, Nam JH, Lee HC, Chung IJ, Park MS, et al. Generation of cytotoxic donor CD8z T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cellderived dendritic cells. Leuk Res. 2004;28(5):517-524.
23. Maggio R, Peragine N, Calabrese E, de Propris MS, Intoppa S, Della Starza I, et al. Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission. Leuk Lymphoma. 2007;48(2):302-310.
24. Mahnke K, Ring S, Johnson TS, Schallenberg S, Schonfeld K, Storn V, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4zCD25z regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol. 2007;37(8):2117-2126.
25. Veldhoen M, Moncrieffe H, Hocking RJ, Atkins CJ, Stockinger B. Modulation of dendritic cell function by naive and regulatory CD4z T cells. J Immunol. 2006;176(10):6202-6210.